Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Organon & Co. chart...

About the Company

organon is a dutch pharmaceutical company started in oss the netherlands. it is famous for "the pil" a birthcontrol pil. organon grew as a company and was taken over by schering plough and later on by merck and continues as msd in the netherlands. in the old days the compant was great, it used to be "gezellig" !

CEO

Kevin Ali

Exchange

NEW YORK STOCK EXCHANGE INC.

$6B

Total Revenue

7K

Employees

$5B

Market Capitalization

6.44

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $OGN News

The top emerging pharmaceutical companies in the US

1d ago, source: GlobalData on MSN

From Organon & Co to Denali Therapeutics, Pharmaceutical Technology lists the top ten emerging US pharmaceutical companies in ...

Organon's prolific asthma med Singulair needs new safety labeling, NY attorney general argues

1mon ago, source: FiercePharma

Organon’s inherited asthma med Singulair is back in the spotlight for the wrong reasons after New York Attorney General Letitia James raised fresh concerns about the drug’s neuropsychiatric ...

Organon & Co Ordinary Shares

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

1mon ago, source: Yahoo Finance

The board of Organon & Co. (NYSE:OGN) has announced that it will pay a dividend of $0.28 per share on the 14th of March. This means the annual payment is 6.0% of the current stock price ...

Organon Stock Is Still Worth A Look

1mon ago, source: Seeking Alpha

In Q4 FY2023, Organon reported strong financial results with an 8% growth in revenue both nominally and at constant currency, surpassing earlier guidance. Revenue for FY2023 was $6.3 billion ...

Organon & Co. (NYSE: OGN)

5d ago, source: The Motley Fool

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health ...

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

1h ago, source: Yahoo Finance

XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial ...

Organon's Earnings: A Preview

1mon ago, source: Benzinga.com

Organon OGN is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here's what investors need to know before the announcement. Analysts estimate that Organon will report an ...

Empowering Women: Organon's Commitment on Women’s Day

15d ago, source: Bangkok Post

Noha Salem, Head of Organon’s Global Women’s Health Policy emphasised the importance of co-creation and a whole-of-society approach, noting the need to work across sectors, involve women in ...

Organon & Co Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...